2nd Immunogenicity & Immunotoxicity Conference

作者:   2013-10-31
  • 会议时间: 2014-01-29至 2014-01-31
  • 会议地点: 美国
  • 电话:0626-2566405
  • 传真:
  • 联系人:Amber Kempf
  • Email: spex@gtcbio.com
  • 联系地址:
  • 会议网址:www.gtcbio.com

 Kasper Lamberth, Head of the Immunogenicity Prediction and Tolerance Department at Novo Nordisk A/S, will give a featured presentation on "Using Immunogenicity Prediction Tools to Identify CD4+ T-cell Epitopes in an rFVIIa Analogue Giving Rise to ADAs?" at the 2nd  Immunogenicity and Immunotoxicity Conference to be held on January 29-31, 2014 in San Diego, CA . Dr. Lamberth will discuss the development of an rFVIIa analogue (Vatreptacog alfa) which was recently discontinued due to the development of ADAs in a phase 3 trial. The talk will present data from in silico and ex vivo immunogenicity prediction tools on full length molecules and on peptides with different length.

编辑: 小林